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Skin Permeation and Cutaneous
Hypersensitivity As a Basis for Making
Risk Assessments of Chromium As a
Soil Contaminant
by Robert E. Bagdon* and Robert E. Hazent
A literature review of experimental and human exposure studies of skin permeation and
cutaneous hypersensitivity reactions evoked by chromium was carried out to provide a basis for
making a risk assessment of chromium as a soil contaminant. In vitro and in vivo studies dem-
onstrated that 1 to 4% of the applied dose of hexavalent and trivalent chromium to guinea pig
skin penetrated skin within 5 to 24 hr after application. Ultrastructural investigations showed
that hexavalent chromium localized intracellularly and extracellularly in the upper layers of
guinea pig epidermis. Only minute quantities of hexavalent chromium are required to elicit a
positive hypersensitivity reaction in susceptible individuals; using a patch dose of20jg, only 2
jig were required to evoke a positive skin reaction in hypersensitive subjects. The potential of
hexavalent chromium to produce a skin sensitization reaction is readily demonstrated using
animal models. The incidence and characteristics ofchromium-induced skin hypersensitivity as
a clinical entity are described. A health effects survey ofpopulations exposed to chromium slag
in soil in Tokyo, Japan extending over 8 years indicated a tendency toward symptoms character-
ized as headache, chronic fatigue, and gastrointestinal complaints, positive occult blood tests,
minute hematuria and albuminuria suggestive ofincipient renal disease, and a tendency toward
an increase in contact dermatitis that was seasonally related. Multicenter patch test titration
studies in human subjects using an incidence ofpositive patch tests of 10%X or less showed that
the threshold for skin hypersensitivity reactions to hexavalent chromium was determined to be
of the order 0.001%, equivalent to 10 ppm or 10 mglkg or 10 mg/L. Analysis of soil samples was
conducted to predict the hexavalent chromium level from the total chromium level. Based on these
data, the cleanup level oftotal chromium in soil is designated as 75 mg/kg. It is proposed that levels
oftotal chromium lower than 75 mg/kg in soil would avoid undue risk ofcontact dermatitis.
Introduction
The potent skin allergenicity of chromium has been
well documented in the literature, and chromium com-
pounds have been reported to be the most frequent
sensitizing agent in man (1-3). Most of the occurrences
ofcontact dermatitis cited are the result ofoccupational
exposures. Consequently, the greatest frequency of
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chromium-induced cutaneous hypersensitivity has been
reported to occur in men ofworking age, i.e., ages 21 to
70 (4). Workers in the building trades are especially
prone to chromium-induced skin hypersensitivity reac-
tions due to the presence of chromium compounds in
cement and other building materials. The early history
ofchromium-related dermatitis, occupational activities,
and industrial compounds associated with chromium-
induced dermatitis and clinical characteristics of
chromium-related allergic contact dermatitis have been
reviewed (5). Geographically, the prevalence of suscep-
tibility to chromium-induced contact dermatitis is wide-
spread. For example, the North American Contact
Dermatitis Group was formed in 1970 to provide a
rational basis for selected antigens for patch test
screening of subjects exhibiting contact dermatitis
lesions. As part of this program, 0.5% potassium
dichromate in petrolatum was applied under a 10-mm112 BAGDON AND HAZES
diameter occlusive patch for 48 hr to 1200 subjects
locate(I in 10 centers in North America (6). Positive test
reactions at the various sites rangecl from 2 to 20%,
with an overall reactivity rate of 8%¢k; in New York, the
positive patch test rate was 9% (Table 1).
The presence of chromite ore processing waste used
as landfill at sites in riesidential, commercial, and in(lus-
trial aleas in Hudson County, New Jersey, represents
an uncommon circumstance with the potential for the
occurrence of significant adverse health effects. In con-
trast to occupational exposures involving a select group
of subjects for a definedl interval (luring the work week
and with the probability that industrial hygiene and
occupational safety measures have been instituted, the
exposure of the general population comprising all age
groups, including childcren and the elderly, with an
undefined incidence of underlying (liseases, vaarying
nutritional status, and long-term, continuous contact
without protective measures presents a particularly
difficult obstacle to arriving at an appropriate risk as-
sessment of chromium undcer these conditions. The U.S.
Environmental Protection Agency considers hexavalent
chromium to be a known human carcinogen by inhalation
exposure and also states that contact dcermatitis is likely
to be associated with low-level hexavalent chromium
exposure (7). However, in contrast to the induction of
cancer, contact dcermatitis may require only a relatively
short-term, superficial exposure.
This report presents the results of a review of the
literature ofskin permeation and cutaneous hypersensi-
tivity reactions evoked by chromium dcerived from both
laboratory experimental investigations and also from
studies of human exposure. The primary objective of
this survey was to collate and evaluate these data to
provide a basis for making a risk assessment of chro-
mium as a soil contaminant. A secondary objective of
this review and evaluation was to delineate possible
areas for additional research.
STRATUM PAPILLA COIRNUM LAYTE I I
I I
I
AGENTS PERMEATIO
Table 1. Positive skin patch test rate to 0.5%c potassium
dichromate in petrolatum at 10 centers in North America, 1972.
Positive patch
Center No. ofsubjects test late
Baangor, Maine 59 10
Detroit, Michigan 20 20
Hanover, Nex Hampshire 197 9
New Orleans, Louisianca 24 12
New York, NeN York 44 9
Portland, Oregon 229 10
Richmond, Virginia 207 4
San Frcancisco, California 126 9
Vaancotuxver, British Columbia 165 8
Total 1200 8
Overall positive p)atch rate 8
Results
Skin Permeation
To gain an undcerstanding ofthe mechanisms involved
in transdermal penetration, skin as a diffusional barrier
can be represented as a multilayer model (Fig. 1). The
stratum corneum is the principal barrier to permeation.
The stratum corneum is nonviable and physiologically
inactive; diffusion through this layer is a passive process.
The viable epidermis can carry out bioconversion. Al-
though epidermal metabolic activity is only a fraction
of that found in the liver, the large surface area of skin
and its proximity to the environment classifies it as a
metabolizing organ ofsignificance.
The epidcermal-metabolizing activity has relevance to
chromium based on a proposed working hypothesis for
skin penetration and pathogenesis of contact sensitiv-
ity (1). It has been postulated that hexavalent chromium
penetrates cells and intracellular organelles relatively
easily and is converted to trivalent chromium intracel-
lularly. The trivalent chromium generated within epi-
TION
FiWI:F;:E 1. A multilayer skin model showing the sequence oftr-ans(lermal permeation ofagents: sorption by stratum corneum, permeation across
viable epidermis, an(d uptake by the capillary network in the (lermal papillariy layei for system distribution. Adaptedl from Chien (8).
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dermal cells reacts with antigenic proteins to evoke the
release ofthe cascade ofinflammatory mediators, which
results in expression ofcontact hypersensitivity.
In contrast, trivalent chromium has been postulated
to penetrate cells relatively poorly and to bind to non-
specific proteins. This may explain the lesser skin hy-
persensitivity potency oftrivalent chromium compared
to hexavalent chromium. The epidermis may also bind
chromium to form adepot. The dermis provides a vehicle
for chromium uptake into the systemic circulation via
the capillary network in the dermal papillary layer. The
dermis may also serve as a reservoir for chromium by
binding it to the collagen matrix.
The methodology employed in the in vitro and in vivo
skin permeation studies has been comprehensively re-
viewed (8-11). One standard in vivo procedure involved
applying a weighed amount of the agent in a container
or patch to the skin, followed by determination of the
remaining agent at the application site after different
time intervals. This procedure is variously referred to
as analysis by difference, remainder analysis, orresidual
patch assay. The technique was extended to determina-
tion of skin penetration of gamma-ray-emitting 51Cr to
guinea pigs in vivo by means of a scintillation counter
and collimator (12). Results are expressed in terms ofa
calculated disappearance constant and also as the dis-
appearance percentage ofthe applied dose from the ap-
plication site over a 5-hr interval. This procedure may
underestimate skin penetration because chromium
present in the skin in a depot would be detectable by
the scintillation counter and would be calculated as part
ofresidual agent at the skin surface.
The remainder analysis technique was used to deter-
mine skin penetration ofhexavalent and trivalent chro-
mium in guinea pigs in vivo (13). Skin penetration was
concentration dependent for both compounds. Maximal
skin penetration for hexavalent chromium amounted to
4% of the applied dose/5 hr at 0.261 M (Fig. 2). For
trivalent chromium, this was observed at 0.017 M
(equivalent to 0.5%, the standard patch test concentra-
tion) and amounted to 2.2%/5 hr (Fig. 3). At 0.261 M,
the skin permeation rate of hexavalent chromium was
690 juM/cm2/hr, 2-fold higher than trivalent chromium,
which was 330juM/cm2/hr (Fig4.) Additional studies with
hexavalent chromium as sodium chromate in guinea pigs
in vivo indicated that skin penetration was higher with
increasing alkaline pH (6.5-12.8) compared to chromium
solutions ofpH 5.6 and lower (5.6-1.4) (14).
Another in vivo experiment was conducted wherein
51Cr hexavalent chromium as sodium chromate was ap-
plied to the skin of guinea pigs, and skin permeation
was determined by assay ofthe 51Cr content present in
excreta and organs after 24 hr (15). In guinea pigs, skin
penetration of chromium amounted to 1.30% of the ap-
plied dose after 24 hr, and this was increased about
9-fold to 12.50% of the applied dose/24 hr by pretreat-
ing the skin with alkali (Table 2).
Ultrastructural investigations have also been carried
out to determine the distribution of chromium in the
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FIGURE 2. Skin permeation ofsodium chromate in guinea pigs in vivo:
disappearance ofdermal dose 51Cr (13).
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1000
900 A = 0.5% Standard Patch Test Concentration
800 NC = Not Calculated
O: 700 O -O CrV!
,o 10-600 * 0- Cr!!! .2 600
500
^ 400
300 _- .
C,,
200
0.017A 0.261
Molor Concentration
FIGURE 4. Skin permeation rate of sodium chromate and chromic
chloride in guinea pigs in vivo (13).
epidermis of nonsensitized and sensitized guinea pigs
(16). In both groups, chromium rapidly penetrated the
skin and was found localized intracellularly and in the
extracellular space in the upper epidermal layers, in-
cluding the horny, granular, and upper spinous layers.
However, the basal and suprabasal cells showed only
extracellular and plasma membrane localization with-
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Table 2. Skin absorption ofchromium in guinea pigs using
percent ofdose in organs and excreta as end points (15).
% Applied dose/24 hr
Group Organsa Excreta Total
Chromate (no pretreatment) 0.19 1.11 1.30
Chromate + sodium
hydroxide (pretreatment)" 2.48 9.97 12.50
alleart, liver, spleen, kidneys, lung. bo0.5 N NaOH, three times daily for 1 week.
out intracellular penetration ofchromium. The Langer-
hans cells showed activation characterized by increased
number oforganelles, endocytic formation, and Berbeck
granules, but intracellular localization ofchromium was
not discernible. This characteristic intraepidermal dis-
tribution my be related to the intracellular conversion
of hexavalent chromium to the immunogenic trivalent
form. In addition, these results also suggest that intra-
cellular localization of chromium into activated Langer-
hans cells is not required for effective presentation of
the hapten to T-cells.
Skin penetration of chromium can also be enhanced
by administration via iontophoresis. In guinea pigs,
iontophoresis increased skin permeation of chromium
over 7-fold during the first hour and over 3-fold during
1 to 5 hr of administration compared to epicutaneous
administration (17).
Quantitation ofthe Hypersensitivity
Reaction
Only minute quantities of chromium are required to
penetrate skin to elicit a positive hypersensitivity reac-
tion in susceptible individuals. Using a patch dose of
20 ,ug of sodium chromate, only 2 ,ug was required to
evoke a positive skin reaction in hypersensitive sub-
jects (18). There was little difference in amount of skin
permeation of chromium in normal individuals at patch
removal after 48 hr of application. After 1 month, the
amount of chromium in skin of normal individuals was
markedly depleted and was even less in hypersensi-
tive individuals (Table 3). This latter finding may be
explained by the shedding of stratum corneum and
superficial epidermal cells as a result ofthe inflammatory
skin reaction at the patch test site. Thus, based on both
experimental and human exposure studies, the very
small amounts ofchromium required to invoke a hyper-
sensitivity reaction can be readily attained in skin.
Immunologic Mechanisms of
Chromium Contact Dermatitis
Chromium contact dermatitis is a delayed hypersen-
sitivity reaction classified as a type IV cell-mediated
immune response. The development of chromium con-
tact dermatitis has been described as occurring in four
phases (1). In phase I, the refractory phase, skin
Table 3. Quantitative aspects ofhexavalent chromium
sensitization.
Concentration at skin application site, pg
Subjects At patch removal, After 1 month
Normal
A 1.6 0.22
B 1.6 0.13
Hypersensitive
C 1.8" 0.02
D 2.1" None
,Patch dose ofsodium chromate 20.8 pg, applied for 48 hr.
"Positive skin reaction characterized by erythema, infiltration, and
papulae (18).
inflammation does not occur, but the chromium hapten
penetrates the skin and conjugates with specific epi-
dermal proteins. In phase II, the induction phase, the
hapten conjugate interacts with T-lymphocytes. In
lymph nodes, T-lymphocytes are transformed into
immunoblasts and divide into memory and effector cells.
In phase III, the elicitation phase, a secondary chromium
challenge activates the effector cells, releasing the cas-
cade of mediators that cause inflammation of the skin.
In phase IV, the persistence phase, effector lymphocytes
continue to recognize the chromium-hapten conjugate,
and the inflammatory reaction in skin continues.
Animal Models of Chromium-induced
Delayed-Type Hypersensitivity
Classically, guinea pig sensitization tests have been
used to assess the potential of agents to evoke skin
sensitization reactions in human subjects. All of these
guinea pig tests involve induction procedures using the
test agent followed by a rest interval and then a subse-
quent challenge with the test agent. The various types
of guinea pig sensitization tests including the Draize,
open epicutaneous, Buehler, Freund's complete adju-
vant, optimization, split adjuvant, and maximization
tests have been reviewed (19). Hexavalent chromium
has been shown to be a potent skin sensitizer in guinea
pig tests (20,21). The propensity for chromium to elicit
skin sensitization in guinea pigs is a probable explana-
tion for selection of this species for skin permeation
studies to obtain correlative data.
More recently, an alternative sensitization test, the
mouse ear swelling test (MEST) has been developed
(22). In addition, a method for the calculation and clas-
sification of relative potencies of dermal sensitizers in
animal and human test systems has been proposed (23)
and is shown in Table 4. Using this approach, the sensi-
tization potential ofpotassium chromate was compared
with p-phenylene diamine in the MEST, guinea pig
maximization, and guineapig closed patch tests and also
with the results of patch tests in human subjects (24).
These results are shown in Table 5. Based on this com-
parison, it was stated: "Potency estimates on potassium
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Table 4. Potency indices and corresponding
hypersensitivity potential rankings.
Ranking ofskin
Class Potency index hypersensitivity potential
I > 4.0 Severe
II 4.0 > 3.0 Strong
III 3.0 > 2.0 Moderate
IV 2.0 > 1.0 Mild
V 1.0 > 0.0 Weak or questionable
Table 5. Comparative sensitization potential ofpotassium
dichromate andp-phenylene diamine in animal and human
test systems.
% Sensitized
MESTa Guinea pig
Agent % Sensitized % Swelling GPMTb closedpatch Human
p-Phenylene 67 109 100 100 53
diamine
Potassium 40 114 75 15 (IM)c
dichromate
aMEST, mouse ear swelling test.
bGPMT, guinea pig maximization test.
c(II), strong sensitizer (23).
dichromate as a sensitizer indicate it to be similar to p-
phenylene diamine and hexamethyldiisocynate as a
sensitizer" (24).
Chromium-Induced Skin
Hypersensitivity As a Clinical Entity
Allergic contact dermatitis from chromium as a dis-
tinct clinical entity that arises from numerous types of
occupational exposure has been extensively reviewed
(1,2,5,25,26). It is important to recognize that there is
no relationship between the classic chromium ulcer le-
sion that occurs in skin and mucous membranes and
allergic sensitization ofskin.
Beginning in 1925, occupationally related allergic
hypersensitivity associated with positive patch tests was
reported in the literature. In 1950, the report on chro-
mium as the causative agent in cement dermatitis fur-
ther focused attention on chromium-induced cutaneous
hypersensitivity reactions (27). The early history of
chromium-related dermatitis has been reviewed by
Adams (5).
Chromium-induced allergic contact dermatitis is
characterized as generally eczematous in appearance,
with the time required for clinical manifestation follow-
ing exposure to be variable, sometimes occurring years
after initial contact. The lesions are chronic or some-
times diminish followed by recurrent relapse. Most of
the lesions occur in the fingers and finger webs, front of
wrists, and the backs of hands, but some reports state
that lesions occur at other sites. The pattern of lesions
is highly variable and has been variously described as
resembling nummular, seborrheic, stasis, or atopic
dermatitis. Other reports cite the resemblance of chro-
mium dermatitis to ragweed dermatitis.
There are several reports indicating that exposure to
sunlight or short wavelength ultraviolet light exacer-
bates the severity of chromium dermatitis, and other
studies indicate that the incidence is seasonal, most of-
ten occurring between April and mid-November, with
the peak occurring in September (1,2,5). Some case
reports emphasize the occurrence of severe pruritis ei-
ther before or concomitant with frank skin lesions (26).
The preponderance of chromium dermatitis in males
most probably reflects a greater occupational exposure.
A clear-cut dose-response relationship has not been
established; lower concentrations of chromium have
caused a greater incidence ofhypersensitivity reactions
than observed at higher concentrations.
The health effects ofchromium dermatitis are signifi-
cant. The lesions have been reported to persist for sev-
eral years in many subjects and significant work time
loss has occurred. The chronicity ofchromium dermatitis
together with the unavailability ofspecific treatment is
the basis of the relatively poor prognosis generally
given. Maintenance ofchromium levels as low as possible
in the environment is emphasized, but this strategy is
more feasible in the workplace than in settings involv-
ing exposure to the general population.
Health Effects Survey ofPopulations
Exposed to Chromium Slag in Soil
Tokyo, Japan
Whereas there are extensive data available on the
health effects of chromium compounds as a result of
occupational exposure, only limited information is avail-
able concerning the health status following environ-
mental exposure ofgeneral populations. In this context,
the longitudinal health effects survey being conducted
by the Tokyo Metropolitan Government Bureau of
Sanitation (28) is noteworthy.
In 1973, contamination from chromium slag was dis-
covered at a construction site ofthe Tokyo subway sys-
tem. The site was formerly owned by a chemical indus-
try company. Based onthese findings, along-termhealth
survey project was initiated, comparing subjects in con-
taminated areas with individuals in noncontaminated
(control) areas. The health effects survey has currently
completed 8 years and is continuing; interim reports
have been issued for surveys conducted for the years
1978-1979, 1980-1981, 1982-1983, and 1984-1985.
The survey has used three contaminated block areas
and two control block areas in the Tokyo district. The
subjects are housewives; a total of 259 subjects in the
contaminated areas and 177 subjects in the control ar-
eas were evaluated. The evaluation consisted of: a) an
interview form and questionnaire (Okayama University
Medical Interview Form) to delineate signs and symp-
toms as reported by the subjects; b) an in-depth medical
examination including clinical interview, physical ex-
amination, otolaryngological and dermatological exami-
115BAGDON AND HAZEN
nations, clinical chemistries, blood chromium levels, uri-
nalysis, and pulmonary function tests.
In the fourth report, covering the years 1984-1985
(28), subjects in the contaminated areas reported a ten-
dency toward a higher incidence of complaints charac-
terized as headache, heaviness in the head, chronic fa-
tigue, dizziness, diarrhea, and constipation compared to
the control subjects. There also was a trend toward an
increase in positive occult blood tests, minute hematuria,
and albuminuria in subjects located in the contaminated
areas. Further analysis using a positive (++) occult test
or over and RBC in the urine of 20 to 25 or more pro-
vided the abnormality rates shown in Table 6.
These results suggest that there is a trend toward
incipient kidney disease that may become manifest as
the epidemiologic survey is continued. Toward this end,
the committee directing this survey of health effects
from chromium contamination plans to include sul-
fosalicylic acid qualitative tests for low molecular weight
urinary protein in the renal function test panel in fur-
ther examinations.
The results of the dermatological examinations indi-
cated an increase in abnormalities ofthe skin in subjects
in the contaminated areas during the summer months
but not during the winter months. Overall, there was
an increase in contact dermatitis and eczema of the
hands in the contaminated areas compared to the con-
trols. This seasonal trend is noteworthy in view of re-
ports indicating that exposure to sunlight or short
wavelength ultraviolet light exacerbates the severity
of chromium dermatitis as previously cited (1,5). The
committee directing this health effects survey also plans
to follow up these observations of dermatologic abnor-
malities in the chromium-exposed population.
Threshold Concentration Required for
Positive Hexavalent and Trivalent
Chromium Patch Tests
One approach to assessing the susceptibility of popu-
lations to chromium-induced dermatitis is to use the
patch test titration technique. In this procedure, the
test population, almost invariably hypersensitive sub-
jects to contact dermatitis, are patch tested using suc-
cessively decreasing concentrations of hexavalent or
trivalent chromium to determine the threshold concen-
tration for evoking a positive skin reaction.
Table 6. Abnormality rates.
Incidence ofpositive occult blood
Area testsa and hematuria,h %
Contaminated area no. 1 8.4
Contaminated area no. 2 10.2
Contaminated area no. 3 10.6
Control area no. 1 4.7
Control area no. 2 2.1
aOccult blood test = ++ or over.
'Hematuiia = 20 to 25 RBC or more in the urine.
Several investigators have provided summary tab-
ulations ofa series ofpatch titration tests. Table 7 rep-
resents a tabulation ofpatch titration tests ofhexavalent
chromium compounds. Patch titration studies ofdichro-
mate at concentrations ranging from 0.5 to 0.001% are
shown in Table 8. In a similar patch test titration study,
14 subjects were challenged with dichromate at concen-
trations ranging from 0.5 to 0.00025% (35). These re-
sults are shown in Table 9. In a direct comparison in 50
chromium-sensitive subjects, chromate evoked a posi-
tive patch test rate in 8% of the subjects at 0.001%
compared to 4% with 0.01% dichromate (34).
Thus, in several multicenter studies involving 301
challenge tests in human subjects and employing an
incidence of positive patch tests of 10% or less, the
threshold concentration for skin hypersensitivity reac-
tions to hexavalent chromium was determined to be of
the order of 0.001%, equivalent to 10 ppm, 10 mg/kg or
10 mg/L.
Skin hypersensitivity data for trivalent compounds in
human subjects are limited; moreover, the sensitization
potency varies with the trivalent chromium salt tested.
Table 10 contains the results of representative patch
titration studies ofthe sulfate, nitrate, and chloride salts
of trivalent chromium. While there are fewer patch
titration studies available for trivalent chromium as
compared to hexavalent chromium, and the sensitiza-
tion potency varies with the salt tested, it is feasible to
designate at least a provisional threshold concentration
for skin sensitization evoked by trivalent chromium
compounds.
Using the data obtained with the sulfate and nitrate
salts and employing an incidence of 10% or less, an ap-
proximate threshold concentration for evoking skin
hypersensitivity by trivalent chromium compounds is
of the order of 0.05% or 500 ppm or 500 mg/kg. This
threshold level is 50-fold higher than that determined
for hexavalent chromium compounds.
Table 7. Patch titration studies ofhexavalent chromium
compounds in human subjects.a
Concentration Total no.
Hexavalent ofhexavalent of No. of % of
chromium chromium subjects positive total
compound compound challenged subjects subjects
Potassium 0.05 33 11 33
chromate 0.02 10 30
0.005 9 27
0.001 3 9
Chromic acid 0.05 13 5 39
0.01 2 15
0.005 5 39
0.001 1 8
Potassium 0.1 13 14 42
dichromate 0.05 17 52
0.01 2 6
aModified from Haines and Niebor (1).
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Table 8. Patch titration studies ofdichromate in human
subjects (29).
Dichromate concentration, %
Reference 0.5 0.2 0.1 0.005 0.01 0.001 Total n
(30) n 2 8 5 15
13 53 13
(31) ii 10 7 5 2 24
% 42 29 21 8
(32) ?? 49 35 13 97
% 51 36 13
(33) nI 1 4 25 4 1 35
% 3 11 71 11 3
(34) n 23 25 2 50
% 46 50 4
Total ?I 60 4 92 33 29 3 221
%b 27 2 42 15 13 1
aPercent of subjects with positive skin reaction of total number of
subjects tested within each study.
bCumulative percent ofsubjects with positive skin reaction oftotal
number ofsubjects tested at each concentration in the studies.
Table 9. Patch titration studies ofdichromate in human
subjects (35).
Dichromate concentration, % we Percent
0.5 14 100
0.25 10 71
0.025 3 21
0.0025 2 14
0.00025 1 7
Total no. ofsubjects 14
Table 10. Patch titration studies oftrivalent chromium
salts in human subjects.
Trivalent No. of
chromium Total no. positive
salt ofsubjects Concentration subjects Percent Reference
Sulfate 28 0.50% 12 43 (1)
0.10% 7 25
0.05% 3 11
Negativea 6 21
Nitrate 28 0.50% 5 18 (1)
0.10% 2 7
0.05% 3 11
Negative 18 64
Chloride 17 0.50 M 11 (36)
22 0.07 M 22
aNegative indicates no reaction or no response.
Derivation of a Risk-Based
Chromium Level in Soil
Contaminated with Chromite Ore
Processing Residue
Contact dermatitis is one ofthe few health end points,
other than respiratory cancer, that is likely to be asso-
ciated with low-level hexavalent chromium exposure.
Based on epidemiologic surveys using the positive patch
test rate to hexavalent chromium as an index (Tables 7
and 8), allergic contact dermatitis is a common acute
effect resulting from exposure ofthe skin to low levels
of chromium. From a review of these surveys it has
been determined that at concentrations of hexavalent
chromium in solution ofless than 0.001% (10 mg/L), the
incidence of contact dermatitis will be reduced to less
than 10% in chromium-sensitive subjects. A source of
uncertainty in using these data for a risk assessment
for soil is the comparison ofparts per million in solution
to parts per million in soil. For a number of reasons it
was concluded that an assumption of equivalence was
the most appropriate. The 10 mg/L ofhexavalent chro-
mium in the solution used for a patch test would have
the same potential for eliciting a response as 10 mg/kg
(10 ppm) hexavalent chromium in soil. Preliminary un-
published data from the New Jersey Department of
Environmental Protection have shown more hexavalent
chromium extracted from the chromite ore processing
residue by a neutral extraction than by the alkaline
digestion method used for the analysis of hexavalent
chromium in waste (41). Therefore, a volume of sweat
(approximately the same composition as the neutral ex-
traction medium) equal to a volume of processing resi-
due on skin should lead to at least the same concentra-
tion in solution as was contained in the soil. It is also
apparent that as the sweat evaporates, a higher concen-
tration will be achieved.
Since there is no method of analysis for hexavalent
chromium in soil that is currently approved by the U.S.
Environmental Protection Agency, it was necessary to
use previous analysis of Hudson County, New Jersey,
soils to construct a ratio of hexavalent to total chro-
mium at contaminated sites and then express the ac-
ceptable soil cleanup levels in terms oftotal chromium.
The relationship between hexavalent and trivalent
chromium is a dynamic one, which is affected by soil
type and mineral content, pH, solubility, and other fac-
tors (40). These factors vary over times and between
locations, so that the hexavalent/total chromium rela-
tionship that exists in one sample may be different at
another time or location.
In orderto carry out this risk assessment, soil samples
were collected from approximately 40 sites in Hudson
County, New Jersey (41). Soil total chromium levels
were available for 994 samples, while hexavalent chro-
mium levels were available for 345. From these data,
statistical analysis were performed by the New Jersey
Department of Environmental Protection to enable the
prediction of hexavalent chromium level from total
chromium measurements. Since only short-term expo-
sure is necessary to elicit a skin reaction, the estimated
95th percentile of the sample distribution of the ratio
between hexavalent and total chromium (0.14) is the
most reasonable figure to use when calculating a target
soil concentration that protects against contact
dermatitis. This target level, approximately 75 mg/kg
(10 mg/kg/0.14), is the concentration of total chromium
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that would not be expected to result in a hexavalent
chromium level greaterthan 10 mg/kg in Hudson County
soil containing the process residue (37).
Due to the fact that the cleanup level is based on the
potential for developing contact dermatitis, no distinc-
tion is necessary between large and small sites or dif-
ferent sites uses.
Discussion
Selection of allergic contact dermatitis as a signifi-
cant toxic end point to arrive at an appropriate risk
assessment of chromium waste as a soil contaminant
has a valid basis. Occupationally related contact
dermatitis resulting from chromium exposure with re-
sulting work time orthe necessity to change occupations
to reduce disability has been well documented. However,
there is little information available regarding skin sen-
sitivity evoked by long-term exposure to the general
population, including children and the elderly. An 8-
year follow-up survey in housewives exposed to soil
contaminated with chromium slag at a construction site
in Tokyo, Japan (28) indicated a tendency toward an in-
crease in subjective symptoms such as headache, chronic
fatigue, and gastrointestinal effects; a tendency toward
an increase in positive occult blood tests in urine, minute
hematuria, and albuminuria; and a seasonal increase in
the incidence of contact dermatitis during the summer
months. These signs and symptoms are further indica-
tions ofthe potential adverse effects oflong-term expo-
sure to chromium to general populations.
The seasonal occurrence of increased contact der-
matitis is of interest in view of reports indicating that
exposure to sunlight or short wavelength ultraviolet
light exacerbates the severity ofchromium der-matitis.
Other factors that add to the complexity of evaluating
chromium-induced skin hypersensitivity are the variable
patterns of the skin lesions, persistence, lack of rever-
sibility or periodic exacerbations, lack of a strict dose-
response relationship, long latency for manifestation of
skin lesions in some individuals after exposure, lack of
specific treatment other than removal from the con-
taminated environment, and occurrence of other
effects on skin, such as severe pruritis.
It has been amply demonstrated that only minute
amounts of hexavalent chromium are required to pen-
etrate skin to elicit delayed contact dermatitis in hyper-
sensitive individuals. Forexample, using a 20 ,ugpatch of
sodium chromate, only 2 jg had to penetrate skin in or-
der to evoke a positive skin reaction in hypersensitive
subjects (18). In vitro and in vivo studies carried out in
guinea pigs demonstrated that hexavalent chromium
can penetrate skin readily, amounting to 1 to 4% of the
applied dose within 5 to 24 hr.
Ultrastructural studies using guinea pig skin also
showed that hexavalent chromium readily penetrates
skin and has a characteristic intraepidermal distribution
(16). Hexavalent chromium localized both intracellularly
and in the extracellular space in the upper epidermal
layers, i.e., the stratum corneum, granular, and upper
spinous layers. However, hexavalent chromium did not
penetrate into the intracellular regions ofthe suprabasal
and basal cells, and distribution in these lower epidermal
layers was limited to the extracellular space and at the
plasma membrane. This characteristic distribution may
be consistent with the proposal that hexavalent chro-
mium is required to penetrate epidermal cells to be
converted intracellularly into the trivalent form, which
is ultimately involved in eliciting the immunologic re-
sponse in skin. A diversity of animal models including
guinea pigs and mice have conclusively demonstrated
that hexavalent chromium is a potent sensitizer of skin
under these experimental conditions (22-24).
Multicenter patch titration studies have shown that
an approximate threshold concentration of hexavalent
chromium can be determined that will evoke a skin sen-
sitization reaction in human subjects. In designating a
threshold as a criterion, the concentration ofhexavalent
chromium that evokes a positive skin hypersensitivity
patch test reaction in 10% or less ofthe population was
employed; this criterion is equivalent to a lowest ob-
served effect level. Thus, the threshold concentration
for skin sensitization ofhexavalent chromium compounds
was determined to be ofthe order of0.001%, and this is
a level below which 90% or more ofthe exposed popula-
tion will not exhibit a positive reaction. The proposed
cleanup level of75 mg/kg oftotal chromium should result
in an incidence of contact dermatitis that is less than
10% ofthe exposed general populations.
This study was carried out with support granted to R.E.B. by the
Office of Science and Research, New Jersey Depaitment of Environ-
mental Protection.
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